NCT05173233尚未招募不适用
Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 67
- 主要终点
- Change of Tricuspid Regurgitation Grade
研究概览
简要总结
The present clinical trial is performed to evaluate the effectiveness and safety of transcatheter tricuspid annuloplasty system manufactured by Shanghai Huihe Healthcare technology Co.,Ltd. for the treatment of subjects with severe or worse tricuspid regurgitation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥60, male or female;
- •patients with severe or above secondary tricuspid regurgitation (TR≥4+) (secondary tricuspid regurgitation: tricuspid regurgitation caused by right atrial lesions, right ventricular cardiomyopathy, right ventricular myocardial infarction, left ventricular valvular disease, congenital heart disease and other diseases);
- •A multidisciplinary cardiac team (at least 2 doctors) consisting of cardiovascular physicians, cardiovascular surgeons, radiologists, anesthesiologists, etc., considered the subject to be at high risk for surgery and expected to benefit from tricuspid valve repair;
- •Left ventricular ejection fraction LVEF≥40%;
- •The subject voluntarily participates in the clinical trial and agrees or his/her guardian agrees to sign the informed consent.
- •Tricuspid regurgitation symptoms, such as chest tightness, asthma, shortness of breath, lower limb edema, ascites;
- •NYHA grade 2 to 4;
- •Patients who received tricuspid valve optimal drug therapy for ≥ 30 days were in stable condition;
- •In the case of the following diseases: mitral regurgitation, atrial fibrillation, coronary disease and heart failure, drug treatment should be ≥ 30 days or ≥ 30 days after instrumental treatment and the patient's condition is stable.
排除标准
- •patients with primary tricuspid regurgitation;
- •Patients with systolic pulmonary artery pressure ≥55 mmHg;
- •Patients with tricuspid valve or annuloplasty or tricuspid related procedure;
- •Patients with posterior tricuspid annulus calcification;
- •Evidence of mass, thrombosis or vegetations in the heart, jugular vein and superior vena cava;
- •patients with moderate or higher aortic stenosis, mitral stenosis, aortic regurgitation or mitral regurgitation;
- •patients with severely uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);
- •Percutaneous coronary intervention within 1 month;
- •myocardial infarction or known unstable angina within 1 month;
- •Cerebrovascular accident within the past 3 months;
- •patients with active endocarditis or active rheumatic heart disease;
- •Patients with coagulation dysfunction, hypercoagulability or anemia (hemoglobin < 90 g/L);
- •patients with acute infection or other severe infection;
- •Patients with active peptic ulcer or active gastrointestinal bleeding;
- •severe end-stage diseases (such as malignant tumor, severe lung disease, liver disease, renal failure) with a life expectancy of less than one year;
- •Patients with known allergies or contraindications to the raw materials or drugs (such as antiplatelet drugs and anticoagulants) of the test products;
- •Persons addicted to alcohol, drugs or drugs;
- •Patients with cognitive impairment;
- •patients with histories of epilepsy or mental illness;
- •Participate in any other clinical trial (other than a registry study) within 30 days prior to signing the informed consent;
- •have a previous implantation of a pacemaker or defibrillator, or plan to implant a pacemaker or defibrillator;
- •Tricuspid stenosis;
- •Ebstain syndrome;
- •The anatomy of tricuspid annulus could not be assessed by TEE and TTE;
- •Hemodynamic instability;
- •chronic dialysis patients;
- •women who are pregnant during pregnancy, breast-feeding or during the clinical study;
- •Other conditions that the investigator considers inappropriate for participation in the clinical trial.
结局指标
主要结局
Change of Tricuspid Regurgitation Grade
时间窗: 1-year after operation
Change of Tricuspid Regurgitation Grade assessed by corelab than baseline
All-cause mortality
时间窗: 1-year after operation
次要结局
- The success rate of post operation 12 months(2 years, 3years, 4 years, 5 years)
- Success rate of device implantation(intra-procedure)
- NYHA(1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years)
- Change of Tricuspid Regurgitation Grade(1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years)
- Change in echocardiographic parameters(1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years)
- Kansas City Cardiomyopathy Questionnaire (KCCQ)(1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years)
- 6 minutes walk distance(1 month, 6 months, 1 year, 2 years, 3years, 4 years, 5 years)
研究者
相似试验
Unknown
不适用
MitraClip for Severe TRTricuspid RegurgitationNCT02863549LMU Klinikum100
Unknown
不适用
Feasibility Study of Dragonfly System for Severe Tricuspid RegurgitationTricuspid RegurgitationNCT04921605Hangzhou Valgen Medtech Co., Ltd10
Unknown
不适用
Safety and Feasibility of the Transcatheter Tricuspid Valve Repair System (Trialign)Tricuspid RegurgitationNCT04936802Xijing Hospital5
已完成
不适用
TRICUS STUDY - Safety and Efficacy of the TricValve® DeviceSevere Tricuspid RegurgitationNCT03723239P+F Products + Features GmbH9
招募中
不适用
Feasibility Study of Treating Tricuspid Regurgitation With K-ClipTM Transcatheter Annuloplasty SystemTricuspid RegurgitationNCT05434507Shanghai Huihe Medical Technology Co., Ltd10